Current studentsExisting staffContact us
 

Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation

Simple item page
dc.contributor.authorHijazi, Z.
dc.contributor.authorAulin, J.
dc.contributor.authorAndersson, U.
dc.contributor.authorAlexander, J.
dc.contributor.authorGersh, B.
dc.contributor.authorGranger, C.
dc.contributor.authorHanna, M.
dc.contributor.authorHorowitz, J.
dc.contributor.authorHylek, E.
dc.contributor.authorLopes, R.
dc.contributor.authorSiegbahn, A.
dc.contributor.authorWallentin, L.
dc.date.issued2016
dc.description.abstractObjective: Atrial fibrillation (AF) is a risk factor for stroke and mortality and the prothrombotic state has been linked to inflammation. In this study we evaluated the relationship between inflammatory biomarkers at baseline and future risk of cardiovascular events in the Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Methods: The ARISTOTLE trial randomised 18 201 patients with AF to apixaban or warfarin. Interleukin 6 (IL-6) and C reactive protein (CRP) were analysed in plasma obtained at randomisation from 14 954 participants, and median follow-up was 1.9 years. Association between quartile groups of IL-6 and CRP and outcomes were analysed by Cox regression adjusted for clinical risk factors and other cardiovascular biomarkers (NT-proBNP, troponin, GDF-15, cystatin C). Results: The IL-6 median level was 2.3 ng/L (IQR 1.5–3.9), median CRP level was 2.2 mg/L (1.0–4.8). IL-6 and CRP were significantly associated with all-cause mortality independent of clinical risk factors and other biomarkers (HR (95% CI) 1.93 (1.57 to 2.37) and 1.49 (1.24 to 1.79), respectively, Q4 vs Q1). IL-6 was associated with myocardial infarction, cardiovascular mortality, and major bleeding beyond clinical risk factors but not in the presence of cardiovascular biomarkers (NT-proBNP, troponin, GDF-15, cystatin C). Neither inflammatory biomarker was associated with stroke/systemic embolism. Risk prediction for stroke, death and major bleeding was not improved by IL-6 or CRP when added to clinical risk factors and the other cardiovascular biomarkers (NT-proBNP, troponin, GDF-15, cystatin C). Conclusions: In patients with AF on anticoagulation, after accounting for clinical risk factors and other biomarkers, biomarkers of inflammation were significantly associated with an increased risk of mortality. However, there were no associations with the risk of stroke or major bleeding.
dc.description.statementofresponsibilityZiad Hijazi, Julia Aulin, Ulrika Andersson, John H Alexander, Bernard Gersh, Christopher B Granger, Michael Hanna, John Horowitz, Elaine M Hylek, Renato D Lopes, Agneta Siegbahn, Lars Wallentin on behalf of the ARISTOTLE Investigators
dc.identifier.citationHeart, 2016; 102(7):508-517
dc.identifier.doi10.1136/heartjnl-2015-308887
dc.identifier.issn1355-6037
dc.identifier.issn1468-201X
dc.identifier.orcidHorowitz, J. [0000-0001-6883-0703]
dc.identifier.urihttp://hdl.handle.net/2440/112404
dc.language.isoen
dc.publisherBMJ Publishing
dc.rightsPublished by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
dc.source.urihttps://doi.org/10.1136/heartjnl-2015-308887
dc.subjectAtrial Fibrillation
dc.titleBiomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications